PD-1 Blockade Potential Comes to Light in Sarcoma Subtypes

Author(s):

An immunohistochemistry analysis of a large patient population demonstrated that several subtypes of difficult-to-treat sarcomas may respond to treatment with PD-1 pathway inhibiting immunotherapies, according to findings presented at the 2017 European Cancer Congress in Amsterdam.

Anke van Erp, PhD, MSc

An immunohistochemistry (IHC) analysis of a large patient population demonstrated that several subtypes of difficult-to-treat sarcomas may respond to treatment with PD-1 pathway inhibiting immunotherapies, according to findings presented at the 2017 European Cancer Congress in Amsterdam¹.

Researchers evaluated the expression and clinical association of the key molecules in the PD-1 pathway and its primary ligand, PD-L1, on tumors and on cells in the tumor microenvironment of pediatric and young adult patients with sarcoma. The investigators also looked for the presence of CD8 expression on the tumors and on cells in the microenvironment, which has been associated with superior survival for patients with localized osteosarcoma².

PD-1/PD-L1 expression is only just beginning to garner attention in sarcoma subtypes, says Anke van Erp, PhD, MSc, of the Radboud University Medical Center in Nijmegen, the Netherlands.

“The interaction of PD-1 and PD-L1 results in negative regulation of T-cell activity, which can be blocked by PD-1 antibodies,” she explained.

With her colleagues, van Erp used IHC to evaluate protein expression on primary tumor samples of 217 patients who were stratified by age at diagnosis into cohorts of <18 years and ≥18 years. They evaluated formalin-fixed paraffin-embedded tumor sections of 52 primary osteosarcoma samples, 22 Ewing sarcoma (ES), 42 alveolar rhabdomyosarcoma (ARMS), 80 embryonal RMS (ERMS), 29 synovial sarcoma (SyS), and 9 desmoplastic small round cell tumor (DSRCT) patient samples by IHC for the expression of PD-1 (using clone MRQ-22), PD-L1 (clone E1L3N), and CD8+ cells (clone C8/144B). Samples having fewer than 10% positively staining cells for each marker were classified as negative and positive if samples showed 10% to 50% of stained cells. Samples with ≥50% stained cells for PD-1, PD-L1 or CD8 were determined highly positive for the specific marker.

The investigators found that cell surface PD-L1 expression by tumor cells and immune infiltrates varied significantly by tumor subtype and was most abundant in DSRCT, where it was expressed by 100% of tumor cells. PD-1 tumor cell expression was expressed on 19% of osteosarcoma and ES tumor cells but not on the other subtypes investigated in this series. PD-1 was expressed on 17% of infiltrating lymphocytes in SyS and at levels of ≤6% on the lymphocytes of osteosarcoma, ARMS, and ERMS samples but not by the other subtypes. PD-L1 expression was highest (18%) in ARMS, followed by 16% on ERMS, 13% DSRCT, and 8% in osteosarcoma samples. No PD-L1 expression was seen in SyS or ES samples.

CD8+ expressing cells were found in all subtypes, including in 76% of DSRCT samples, 66% of osteosarcoma, 43% SyS, 41% ES, and in 39% of ERMS samples. In the DSRCT subtype, 13% of the samples had all 3 markers compared to osteosarcoma wherein just 2% of the specimens showed this same staining.

When the investigators explored the association of expression with the clinical outcome of overall survival (OS) at a follow-up of 100 months in sarcoma patients overall, they found no significant association between OS and expression of PD-1, PD-L1, or CD8.

However, they did find a strong correlation in the ARMS subtype where PD-L1 tumor expression significantly correlated with better OS (P = .007) and event-free survival (EFS; P = .007) in patients compared with patients with tumors expressing low or no PD-L1.

The investigators also identified ES patients aged ≥18 years with tumors expressing PD-1 as a cohort that was associated with poorer EFS (P = .018).

Further evaluation of PD-1, PD-L1, and CD8+ expression in patients with sarcoma and metastatic disease is planned. “This research was limited by small samples of these relatively rare sarcoma subtypes but we were able to demonstrate that PD-1and PD-L1 expression and clinical association in sarcoma is subtype dependent; PD-L1 expression in ARMS correlates with better OS and EFS and PD-1 expression on ES and DSRCT tumor cells correlates with worse EFS,” van Erp summarized.

Van Erp noted that this was the first time that high levels of PD-1 expression, either alone or in combination with PD-L1, were demonstrated on the tumors of DSRCT patients, who also showed co-expression of CD8+ cells. Co-chair of the session, Stefan Sleijfer of the Erasmus Medical Center in the Netherlands agreed that the high levels of PD-1, PD-L1, and CD8 expression in DSRCT warrants further investigation into whether PD-1 blockade could have clinical benefit in DSRCT patients.

References

van Erp A, Versleijen-Jonkers Y, Hillebrandt-Roeffen M, et al. Exploring the potential for PD-1 blockade in sarcoma patients. Presented at: 2017 European Cancer Congress; January 27-30, 2017; Amsterdam, the Netherlands.
Palmerini E, Agostinelli C, Picci P, et al. PD1 and PDL1 expression, tumoral microenvironment (TME) characterization and clinical implication in localized osteosarcoma. Presented at: 2016 ESMO Congress; October 7-10, 2016; Copenhagen, Denmark. Abstract 1399PD.